Raymond James Financial
CRNX

Raymond James Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Raymond James Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Sell
43,632
-1,560
-3% -$58K ﹤0.01% 3649
2026
Q1 		$1.64M Buy
45,192
+11,838
+35% +$529K ﹤0.01% 3498
2025
Q4 		$1.55M Buy
+33,354
New +$1.48M ﹤0.01% 3467
2025
Q3 		– Sell
-1,561
Closed -$44.9K – 5347
2025
Q2 		$44.9K Buy
+1,561
New +$48.2K ﹤0.01% 5230

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's CRNX Position: Q2 2026 in Review

Raymond James Financial reduced its Crinetics Pharmaceuticals (CRNX) stake by 3.5% in Q2 2026, selling an estimated $58K and leaving 43,632 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

Raymond James Financial first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.64M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Raymond James Financial held 43,632 shares of Crinetics Pharmaceuticals worth $1.63M as of Q2 2026.
  • Raymond James Financial sold 1,560 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $58K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3649 holding.
  • Raymond James Financial first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Crinetics Pharmaceuticals position peaked at $1.64M in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.